Omnicell signs definitive agreement to acquire Aesynt

Omnicell, Inc., (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced it has entered into a definitive agreement to acquire Aesynt Incorporated. The acquisition would create the broadest product portfolio in the industry with significant offerings in automated dispensing systems, central pharmacy robotics, IV robotics and enterprise analytics. The combined company would support approximately 4,000 acute care facilities worldwide, have annual revenues of over $650 million and have approximately 2,200 employees.

"As hospitals search for ways to provide the best patient care and also the most efficient care, customers are looking for solutions that can be scaled and customized to fit the unique needs of their health system," said Randall Lipps, Chairman, President and CEO, Omnicell. "By adding distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics, this acquisition demonstrates our continued commitment to offer our customers leading pharmacy automation solutions tailored to the specific needs of their facilities and patients. We also expect that as a combined entity we can accelerate innovation in the marketplace by leveraging the combined strengths of the Aesynt and Omnicell teams. Choice, innovation and value make this a great acquisition for Omnicell and our customers."

Aesynt, based in Cranberry Township, Pa., is a leader in enterprise medication management. Specific solutions include:

  • IV Solutions: Full suite of automated and semi-automated solutions for the IV room including hazardous and non-hazardous solutions with IV workflow, compounding software and IV preparation analytics.
  • Central Pharmacy Solutions: Leading solutions including unit dose medication dispensing robots, vertical storage and dispensing of medications, open shelf inventory tracking and unit dose repackaging products and services.
  • Point of Care Solutions: Medication storage and dispensing cabinets for nursing units and operating rooms and narcotic medication storage and dispensing.
  • Enterprise Software: Dynamic, enterprise-wide medication logistics management software, automated procurement and order management, and reporting and analytics for inventory management and medication utilization.

"Omnicell and Aesynt share a passion for and commitment to affordable, safe medication delivery through innovation and automation," said Kraig McEwen, Aesynt CEO. "Today, healthcare organizations embrace Aesynt's robust medication management tools, which complement Omnicell's product portfolio and international footprint. We are delighted to work with the Omnicell team. Our common goal to improve healthcare for everyone will now be realized."


Omnicell, Inc.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Omnicell, Inc.. (2019, June 24). Omnicell signs definitive agreement to acquire Aesynt. News-Medical. Retrieved on September 28, 2022 from

  • MLA

    Omnicell, Inc.. "Omnicell signs definitive agreement to acquire Aesynt". News-Medical. 28 September 2022. <>.

  • Chicago

    Omnicell, Inc.. "Omnicell signs definitive agreement to acquire Aesynt". News-Medical. (accessed September 28, 2022).

  • Harvard

    Omnicell, Inc.. 2019. Omnicell signs definitive agreement to acquire Aesynt. News-Medical, viewed 28 September 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Omnicell receives notification from NASDAQ OMX Group for noncompliance with Nasdaq Listing Rule